Literature DB >> 29128049

Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Zobair M Younossi1, Linda Henry2, Haley Bush3, Alita Mishra4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing global prevalence associated with tremendous clinical, economic, and health-related quality-of-life burden. Clinically, NAFLD is considered the liver manifestation of metabolic syndrome. However, diagnosing NAFLD presents significant challenges due to the limited noninvasive and accurate diagnostic tools available to not only accurately diagnose nonalcoholic steatohepatitis but also to stage hepatic fibrosis, the major predictor of long-term outcomes, including mortality.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Health-related quality of life; Mortality; Prevalence; Risk factors

Mesh:

Year:  2017        PMID: 29128049     DOI: 10.1016/j.cld.2017.08.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  21 in total

1.  Differential expression and bioinformatic analysis of circRNA in nonalcoholic steatohepatitis cirrhosis.

Authors:  Yuexin Fan; Yang Zheng; Jiahui Wang; Tiejian Zhao; Tianjian Liang
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

Review 2.  Fatty liver and cerebrovascular disease: plausible association and possible mechanisms.

Authors:  Sahil Khanna; Neal S Parikh; Lisa B VanWagner
Journal:  Curr Opin Lipidol       Date:  2022-02-01       Impact factor: 4.616

3.  Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma.

Authors:  Jihane N Benhammou; Jonathan Lin; Shehnaz K Hussain; Mohamed El-Kabany
Journal:  Hepatoma Res       Date:  2020-06-18

Review 4.  Human biomimetic liver microphysiology systems in drug development and precision medicine.

Authors:  Albert Gough; Alejandro Soto-Gutierrez; Lawrence Vernetti; Mo R Ebrahimkhani; Andrew M Stern; D Lansing Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-17       Impact factor: 73.082

Review 5.  Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.

Authors:  Amedeo Lonardo; Ayako Suzuki
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

6.  A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment.

Authors:  Chang-Gue Son
Journal:  Integr Med Res       Date:  2018-02-02

7.  Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.

Authors:  Nigel S Cook; Sarthak H Nagar; Akanksha Jain; Maria-Magdalena Balp; Miriam Mayländer; Olivia Weiss; Satabdi Chatterjee
Journal:  Adv Ther       Date:  2018-12-13       Impact factor: 3.845

8.  A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Shanzhou Huang; Chengjun Sun; Yuchen Hou; Yunhua Tang; Zebin Zhu; Zhiheng Zhang; Yixi Zhang; Linhe Wang; Qiang Zhao; Mao-Gen Chen; Zhiyong Guo; Dongping Wang; Weiqiang Ju; Qi Zhou; Linwei Wu; Xiaoshun He
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

9.  Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Pegah Golabi; Natsu Fukui; James Paik; Mehmet Sayiner; Alita Mishra; Zobair M Younossi
Journal:  Hepatol Commun       Date:  2019-06-06

10.  Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis.

Authors:  Hong Xu; Gao-Feng Chen; Yu-Shui Ma; Hong-Wei Zhang; Yang Zhou; Guang-Hui Liu; Dong-Ya Chen; Jian Ping; Yi-Hui Liu; Xin Mou; Da Fu
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.